Stockscreener 앱 받기
1.05
7.08%
-0.08
시간 외 거래:
1.06
0.01
+0.95%
전일 마감가:
$1.13
열려 있는:
$1.09
하루 거래량:
102.66K
Relative Volume:
0.02
시가총액:
$2.37M
수익:
$54.43M
순이익/손실:
$-36.70M
주가수익비율:
-0.3579
EPS:
-2.9334
순현금흐름:
$-19.17M
1주 성능:
-8.70%
1개월 성능:
-9.48%
6개월 성능:
+87.50%
1년 성능:
-41.99%
1일 변동 폭
$1.045
$1.12
1주일 범위
$1.03
$1.17
52주 변동 폭
$0.48
$3.44
Trinity Biotech Plc Adr Stock (TRIB) Company Profile
TRIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRIB
Trinity Biotech Plc Adr
|
1.05 | 4.21M | 54.43M | -36.70M | -19.17M | -2.9334 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Trinity Biotech Plc Adr Stock (TRIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-10-23 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2015-09-03 | 개시 | Raymond James | Outperform |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2008-07-22 | 재확인 | Roth Capital | Buy |
| 2008-03-17 | 재확인 | Roth Capital | Buy |
| 2007-12-10 | 재확인 | Roth Capital | Buy |
| 2007-10-26 | 재확인 | Roth Capital | Buy |
모두보기
Trinity Biotech Plc Adr 주식(TRIB)의 최신 뉴스
Trinity Biotech : 2025 AGM Notice Sent to holders of Ordinary Shares - MarketScreener
TRINITY B ADR : Trinity Biotech plc to Present at Sidoti & Company's Micro-Cap Conference on January 10, 2011 - MarketScreener
Upcoming Stock Splits This Week (August 25 to August 29) – Stay Invested - TipRanks
Trinity Biotech plc Appoints Paul Tivnan as Non-Executive Director - MarketScreener
Trinity Biotech appoints Paul Tivnan to board of directors - Investing.com
Trinity Biotech receives approval for offshore manufacturing of HIV test - Investing.com
TRIB’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test By Investing.com - Investing.com South Africa
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test - Investing.com India
Trinity Biotech receives NY approval for preeclampsia test - Investing.com
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewswire Inc.
Trinity Biotech stock rises on successful CGM calibration-free trial By Investing.com - Investing.com South Africa
Trinity Biotech stock rises on successful CGM calibration-free trial - Investing.com India
Trinity Biotech reports positive results for calibration-free CGM By Investing.com - Investing.com South Africa
Trinity Biotech reports positive results for calibration-free CGM - Investing.com India
Trinity Biotech (TRIB) to Release Earnings on Wednesday - Defense World
Trinity Biotech launches preeclampsia testing service for maternal health By Investing.com - Investing.com South Africa
Trinity Biotech launches preeclampsia testing service for maternal health - Investing.com India
Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call - ACCESS Newswire
Cadence Bank (CADE) Stock: A Year of Market Fluctuations - investchronicle.com
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround - MarketScreener
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic and Financial Performance Transformation - MarketScreener
Trinity Biotech receives WHO approval for offshore HIV test manufacturing - Investing.com
Trinity Biotech Appoints New Interim CFO - Investing.com India
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process - MarketScreener
Trinity Biotech stock hits 52-week low at $0.72 amid challenges - Investing.com
Trinity Biotech stock hits 52-week low at $0.74 amid market challenges - Investing.com
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial - MarketScreener
Trinity Biotech secures US funding for HIV tests - Investing.com
Trinity Biotech faces US aid policy impact, PPP loan scrutiny - Investing.com
Trinity Biotech announces breakthrough in CGM technology - Investing.com
Trinity Biotech Expands Market Reach with New ADS Offering - Nasdaq
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan - MarketScreener
Trinity Biotech plc Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV - MarketScreener
Trinity Biotech : Regains Compliance with Nasdaq Listing Requirements Form 6 K - MarketScreener
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform - MarketScreener
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology - MarketScreener
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market - MarketScreener
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer - MarketScreener
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology - MarketScreener
Trinity Biotech plc Appoints Global Life Sciences Leader Adrian Donohue as Chief Commercial Officer - MarketScreener
Trinity Biotech appoints new biosensor marketing director - Investing.com
Trinity Biotech plc Announces Chief Financial Officer Changes - MarketScreener
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association - MarketScreener
Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development - MarketScreener
Trinity Biotech announces ADS ratio change - Investing.com
Trinity Biotech Announces CE Mark of its Covid-19 IgG Elisa Antibody Test - MarketScreener
TRIBTrinity Biotech Plc Latest Stock News & Market Updates - Stock Titan
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo - Yahoo Finance
TRIB News Today | Why did Trinity Biotech stock go up today? - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Trinity Biotech Plc Adr (TRIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.83%
자본화:
|
볼륨(24시간):